Royal Bank Of Canada Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by Royal Bank Of Canada from $688.00 to $695.00 in a research report report published on Monday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on REGN. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, June 2nd. Finally, Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $841.30.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $571.54 on Monday. The company has a quick ratio of 4.73, a current ratio of 5.39 and a debt-to-equity ratio of 0.09. The firm has a market cap of $61.71 billion, a PE ratio of 14.40, a price-to-earnings-growth ratio of 2.10 and a beta of 0.33. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company’s 50-day moving average price is $537.72 and its two-hundred day moving average price is $601.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $11.56 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of REGN. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management raised its holdings in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Finally, Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.